Depression May Decrease Breast Cancer Screening

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 4
Volume 11
Issue 4

WASHINGTON-A definite link exists between mammography screening and lessened breast cancer mortality, but black women do not take full advantage of cancer screening, according to Janice S. Emerson, research associate, Center for Health Research, Tennessee State University, Nashville. Speaking at the American Psychological Association Conference on Enhancing Outcomes in Women’s Health, she presented findings from an HCFA-funded project, led by Dr. Baqar A. Husaini.

WASHINGTON—A definite link exists between mammography screening and lessened breast cancer mortality, but black women do not take full advantage of cancer screening, according to Janice S. Emerson, research associate, Center for Health Research, Tennessee State University, Nashville. Speaking at the American Psychological Association Conference on Enhancing Outcomes in Women’s Health, she presented findings from an HCFA-funded project, led by Dr. Baqar A. Husaini.

In addition to cost and inconvenience, Ms. Emerson noted, researchers have ascribed this failure of black women to seek mammography screening to other factors, including lack of knowledge about cancer, lack of knowledge about who needs a mammogram, and health care providers’ failure to recommend that women get mammograms. But recent data show that depression is a significant factor as well. Ms. Emerson described a study that examined the relationship between depression and screening mammography as well as the effect of social support on lessening the former and increasing the latter.

An experimental group of 288 black women at least 40 years old received an educational intervention informing them about mammography. A control group of 56 comparable women received no such intervention. Each subject underwent an evaluation for depression and answered questions about her mammography practices and the sources and degree of social support in her daily life, in general and regarding mammograms.

Women who had not gotten needed mammograms showed "a great deal more depressive symptoms" than those who had, Ms. Emerson reported.

Social support specifically related to mammograms, such as participating in discussions about mammography’s benefits, greatly increased the likelihood that a woman would get screened, she said. General social support, however, as measured by the number of friends women mentioned, had no effect on that likelihood except indirectly, insofar as it helped lessen depression.

Interventions aimed at increasing mammography among black women should therefore focus not only on conveying information about mammograms but on the psychological context in which the women live, Ms. Emerson said.

Related Videos
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.
Related Content